{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:02:32Z","timestamp":1790892152361,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018170","name":"Pierre Fabre Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018170","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejca.2025.115253","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T19:59:54Z","timestamp":1737489594000},"page":"115253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015\u20132022)"],"prefix":"10.1016","volume":"217","author":[{"given":"Sidsel","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Lund","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Louise","family":"H\u00f8jholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Wett","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Mark","family":"Mogensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Kj\u00e6r","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte Aaquist","family":"Haslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ellebaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2025.115253_bib1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115253_bib2","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/cncr.25634","article-title":"Prognostic factors for survival in melanoma patients with brain metastases","volume":"117","author":"Davies","year":"2011","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2025.115253_bib3","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/bjc.2011.178","article-title":"Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens","volume":"104","author":"Chiarion-Sileni","year":"2011","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115253_bib4","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","article-title":"Determinants of outcome in melanoma patients with cerebral metastases","volume":"22","author":"Fife","year":"2004","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.115253_bib5","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.annonc.2020.07.004","article-title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","volume":"31","author":"Keilholz","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115253_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2020.10.013","article-title":"Management of melanoma brain metastases: evidence-based clinical practice guidelines by Cancer Council Australia","volume":"142","author":"Hong","year":"2021","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2025.115253_bib7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115253_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1227\/NEU.0000000000000584","article-title":"Postoperative stereotactic radiosurgery to the resection cavity for large brain metastases: clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection","volume":"76","author":"Ling","year":"2015","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejca.2025.115253_bib9","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/neuonc\/noad188","article-title":"The dilemma of radiation necrosis from diagnosis to treatment in the management of brain metastases","volume":"26","author":"Mayo","year":"2024","journal-title":"Neuro Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115253_bib10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Prospective randomized trial of post-operative stereotactic radiosurgery versus observation for completely resected brain metastases","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115253_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115253_bib12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2025.115253_bib13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115253_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.115253_bib15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115253_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/CMR.0000000000000816","article-title":"Real-world data on melanoma brain metastases and survival outcome","author":"Pedersen","year":"2022","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.ejca.2025.115253_bib17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cam4.3716","article-title":"Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases","volume":"10","author":"Moyers","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2025.115253_bib18","first-page":"1","article-title":"Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies","author":"Bander","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2025.115253_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051461","article-title":"Impact of novel treatments in patients with melanoma brain metastasis: real-world data","volume":"15","author":"Derks","year":"2023","journal-title":"Cancers"},{"issue":"April","key":"10.1016\/j.ejca.2025.115253_bib20","article-title":"The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients","volume":"73","author":"Ellebaek","year":"2021","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115253_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cam4.4438","article-title":"Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: a real-world study","volume":"11","author":"Tawbi","year":"2022","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115253_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"issue":"December 2023","key":"10.1016\/j.ejca.2025.115253_bib23","article-title":"Combined immunotherapy in melanoma patients with brain metastases: a multicenter international study","volume":"199","author":"Mandal\u00e0","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.115253_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004509","article-title":"Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG","volume":"10","author":"Franklin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115253_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2217","article-title":"1083MO Brain metastases and survival evaluation in the SECOMBIT trial","volume":"34","author":"Ascierto","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115253_bib26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial","volume":"41","author":"Ascierto","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115253_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115253_bib28","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.1016\/S1470-2045(23)00334-0","article-title":"Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study","volume":"24","author":"Dummer","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.115253_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/pcmr.13116","article-title":"Leptomeningeal disease in melanoma: an update on the developments in pathophysiology and clinical care","volume":"37","author":"Smalley","year":"2024","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.ejca.2025.115253_bib30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejca.2021.02.016","article-title":"Leptomeningeal disease from melanoma\u2014poor prognosis despite new therapeutic modalities","volume":"148","author":"Chorti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2025.115253_bib31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11060-019-03121-2","article-title":"Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)","volume":"142","author":"Ferguson","year":"2019","journal-title":"J Neurooncol"},{"issue":"14","key":"10.1016\/j.ejca.2025.115253_bib32","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1158\/1078-0432.CCR-21-1694","article-title":"Single-cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases","volume":"27","author":"Smalley","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2025.115253_bib33","first-page":"452","article-title":"Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma","volume":"11","author":"Saberian","year":"2024","journal-title":"Neurooncol Pract"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T04:44:47Z","timestamp":1777265087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":33,"alternative-id":["S0959804925000346"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115253","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015\u20132022)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115253","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115253"}}